25 years of the SMN genes: the Copernican revolution of spinal muscular atrophy.

ABSTRACT: The new era of advanced therapies has influenced and changed the views and perspectives of a neuromuscular disease such as spinal muscular atrophy (SMA). Being an autosomal recessive motor neuron disorder, characterized by different degrees of muscle weakness, after 25 years of the discovery of the determinant and modifier genes (SMN1 and SMN2, respectively) three SMN-dependent specific therapies are already approved by FDA (two by EMA), so that worldwide patients are currently under clinical investigation and treatment. This success was the combined effort mainly of patients and families, physician and researchers, advocacy groups and several Institutions together with the support of pharmaceutical companies. Progression trajectories, phenotypes, follow-up and care of the patients are con

SUBMITTER: Tiziano FD 

PROVIDER: S-EPMC7783429 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature